Literature DB >> 25795908

Conventional DMARDs in axial spondyloarthritis: wishful--rather than rational--thinking!

Robert B M Landewé1.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); Spondyloarthritis; Treatment

Mesh：

Substances：

Year:  2015        PMID： 25795908     DOI： 10.1136/annrheumdis-2014-206758

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.

Authors:  Guan-Min Gao; Yan-Min Li; Xiao-Long Zheng; Dong-Bin Jiang; Lei-Lei Zhang; Peng-Hui Xu; Sheng-Yun Liu; Zhao-Hui Zheng; Quan-Cheng Kan
Journal:  Med Sci Monit       Date:  2017-06-19

2.  Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.

Authors:  Monika Hebeisen; Almut Scherer; Raphael Micheroli; Michael J Nissen; Giorgio Tamborrini; Burkhard Möller; Pascal Zufferey; Pascale Exer; Adrian Ciurea
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

Review 3.  Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.

Authors:  James Cheng-Chung Wei; Chin-Hsiu Liu; Jui-Cheng Tseng; Lin-Fen Hsieh; Chun-Hsiung Chen; Hsin-Hua Chen; Hung-An Chen; Ying-Chou Chen; Chung-Tei Chou; Hsien-Tzung Liao; Yi-Chun Lin; Shue-Fen Luo; Deng-Ho Yang; Kai-Jieh Yeo; Wen-Chan Tsai
Journal:  Int J Rheum Dis       Date:  2019-11-27       Impact factor: 2.454
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.